Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

VivaVision Completes $46 Million Funding for Ophthalmology Therapies

publication date: Apr 26, 2021

VivaVision Biotech of Shanghai completed a $46 million Series D financing to develop novel drugs for chronic ocular or dermal inflammatory diseases. VivaVision is developing four molecules including its lead candidate, VVN001, a treatment for dry eye that is being tested in a Phase II study in the US. The company is also developing products for glaucoma. VivaVision was originally incubated by Vivo Biotech, a structure-based drug discovery CRO. The D round was led by Sequoia Capital China. More details....

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital